Home
Conditions
Neoplasms, Plasma Cell

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies

Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Not Yet Recruiting

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

NCT07652905

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China

View Trial Details

Not Yet Recruiting

PET-Enabled Dual-Energy CT in Multiple Myeloma

NCT07646873

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: UC Davis EXPLORER Molecular Imaging Center Sacramento, California, United States

View Trial Details

Not Yet Recruiting

A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

NCT07612787

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations: Centre Hospitalier Universitaire Amiens, France

Centre Hospitalier Universitaire Angers, France

Centre Hospitalier Universitaire Annecy, France

Centre Hospitalier D'Argenteuil Argenteuil, France

View all 30 locations

View Trial Details

Not Yet Recruiting

CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

NCT07648459

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07628595

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: The First Affiliated Hospital with Nanjing Medical University Nanjing, Jiangsu, China

View Trial Details

Not Yet Recruiting

Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study

NCT07634263

Conditions: Behavior, Blood Protein Disorders, Cardiovascular Diseases, +23 more
Locations: Copenhagen University Hospital (Rigshospitalet) Copenhagen, Denmark

Odense University Hospital Odense, Denmark

Sjællands Universitets Hospital Roskilde, Denmark

View Trial Details

Not Yet Recruiting

Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

NCT07191379

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT04579523

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Not Yet Recruiting

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT07624513

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Beth Israel Deaconess Medical Center (BIDMC) Boston, Massachusetts, United States

Brigham and Women's Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Not Yet Recruiting

Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging

NCT07624760

Conditions: AL Amyloidosis, Amyloidosis, Blood Protein Disorders, +23 more
Locations: University Hospital Zurich Zurich, Canton of Zurich, Switzerland

View Trial Details

Neoplasms, Plasma Cell

Neoplasms, Plasma Cell trial results

Related conditions